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Abstract
Background: Hospital-associated infections (HAIs) are reported to increase patient mortality and incur longer
hospital stays. Most studies to date have focused on specific groups of hospitalised patients with a rather short
follow-up period. In this repeated cross-sectional study, with prospective follow-up of 19,468 hospitalized patients,
we aimed to analyze the impact of HAIs on mortality 30 days and 1 year after the prevalence survey date.
Methods: The study was conducted at Haukeland University Hospital, Norway, a large combined emergency and
referral teaching hospital, from 2004 to 2011 with follow-up until November 2012. Prevalence of all types of HAIs
including urinary tract infections (UTI), lower respiratory tract infections (LRTI), surgical site infections (SSI) and
blood stream infections (BSI) were recorded four times every year. Information on the date of birth, admission
and discharge from the hospital, number of diagnoses (ICD-10 codes) and patient’s mortality was retrieved
from the patient administrative data system.
The data were analysed by Kaplan-Meier survival analysis and by multiple Cox regression analysis, adjusted for
year of registration, time period, sex, type of admission, Charlson comorbidity index, surgical operation, use of
urinary tract catheter and time from admission to the prevalence survey date.
Results: The overall prevalence of HAIs was 8.5 % (95 % CI: 8.1, 8.9). Patients with HAIs had an adjusted
hazard ratio (HR) of 1.5 (95 % CI: 1.3, 1.8,) and 1.4 (95 % CI: 1.2, 1.5) for death within 30-days and 1 year,
relative to those without HAIs. Subgroup analyses revealed that patients with BSI, LRTI or more than one
simultaneous infection had an increased risk of death.
Conclusions: In this long time follow-up study, we found that HAIs have severe consequences for the
patients. BSI, LRTI and more than one simultaneous infection were independently and strongly associated
with increased mortality 30 days and 1 year after inclusion in the study.
Keywords: Hospital associated infections, HAIs, Mortality, Prevalence, Blood stream infection, Lower respiratory
tract infection
Background
In industrialized countries, at any given time, more than
one out of twenty patients has a hospital associated in-
fection (HAI) [1–7]. Even if great efforts have been made
to reduce HAIs during the last decades, such infections
are still among the most common complications
affecting hospitalized patients [8]. The risk for HAIs de-
pends on patient related factors, various invasive proce-
dures and treatment provided during hospital stay.
Medical technology and treatment are becoming more
complex every year and more patients with severe
underlying diseases are treated. Consequently, HAIs vary
according to the type of clinical department, with the
highest infection rate usually found in intensive care
units (ICU), neonatal and burn units [3, 5, 6, 9, 10].
HAIs affect a large number of patients in terms of
complications, increased mortality and longer hospital
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stay. HAIs may also affect the quality of life like long term
disability and psychological trauma and are reported as
one of the top leading causes of in-hospital deaths world-
wide [8, 11]. HAIs also impose significant economic con-
sequences on the healthcare system [12–14].
The association between different HAIs and mortal-
ity is well established in previously published studies
[14–19], and such associations are particularly found in
patients with lower respiratory tract (LRTI) [14, 16, 17]
and blood stream infections (BSI) [14, 16, 18, 20]. How-
ever, some of the studies are primarily performed in high
risk units, with a small number of patients, focusing on
one type of HAI, or without taking co-morbidity into
account.
In this study the purpose was to evaluate a possible re-
lationship between various types of HAIs and the risk of
mortality within 30 days and 1 year among 19,468




The study was conducted at Haukeland University Hos-
pital, a hospital trust including a large somatic hospital
and psychiatric hospital, a smaller emergency hospital,
and a specialized orthopedic hospital. All together the
hospital has approximately 1000 somatic beds. It covers
about one million inhabitants in Western Norway, and
is also an emergency hospital for 300,000 people. It pro-
vides all specialties apart from organ transplants, and it
includes large intensive care units with approximately 30
beds, a neonatal unit with 7 beds, and a national burns
center with 5 beds.
Method
The study was designed as a repeated cross-sectional
study with prospective follow-up of life status. Data
collection was performed four times annually from
November 2004 to November 2011, with a one year follow
up for all subjects up to November 2012. All in-patients
on the day of prevalence survey were included in the study
and a total of 26,933 patients were recorded following 32
different surveys. When excluding patients with hospital
stay less than 2 days (by definition not at risk for HAI) or
longer than 250 days, as well as patients with HAIs trans-
ferred from other hospitals and patients with missing in-
formation on LOS, we ended up with a patient cohort of
19,468 (Fig. 1). When a patient had more than one regis-
tration in the surveillance system during the follow-up
period, only the first admission was included.
Ethics
The data was collected as a part of the hospital’ s infection
prevalence survey. According to the Health Research Act,
Norway, quality assurance projects, surveys and evalua-
tions that are intended to ensure that diagnosis and treat-
ment actually produce the intended results do not need
ethical committee approval and patient consent is not
required. Hence, the study was only approved by the
hospital’ s privacy ombudsman [Ref: 2013/9818].
Data collection
The Department of Infection Control has the overall
responsibility for data collection in a local registry
established for the mandatory infection surveillance,
which was linked to the patient administrative sys-
tem. On the day of prevalence survey, dedicated
nurses or physicians in the somatic wards reviewed
all in-patients in an on-line system. The patients’ in-
fection status was identified, and the inclusion day
was defined as the day of the prevalence survey.
HAIs were identified according to a simplified ver-
sion of the definitions developed and recommended
by the Centres for Disease Control and prevention
(CDC), USA [2, 21].
HAIs were defined as any infection identified at least
48 h after hospital admission without evidence of the in-
fection being present or incubating at the time of
1 LOS = Length of stay
Recorded patients 2004-2011
n= 26,933
Patients with ≥ 250 
days LOS1 
n=26LOS














Fig. 1 Flow-chart showing patient inclusion in the study
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admission. All in-patients registered in somatic wards at
the hospital at 8 a.m. on the designated day were
included in the survey.
All types of HAIs were recorded and analysed, includ-
ing symptomatic urinary tract infection (UTI), lower re-
spiratory tract infection (LRTI), blood stream infection
(BSI), and surgical site infection (SSI). HAIs with only a
few included cases such as skin, soft-tissue infections
and gastrointestinal infections were analysed together as
“other infections”. Patients with more than one type of
infection simultaneously were analysed as a separate
group. The prevalence of surgical site infections was
analysed including all patients for overall prevalence and
among operated patients only in the remaining analysis.
The following variables were recorded for each patient:
sex, age, season of admission (spring, summer, autumn
and winter), elective versus emergency admission, surgi-
cal procedure, use of urinary tract catheter (permanent
and intermittent catheter) and antibiotic therapy. Date
of admission was automatically collected from the
patient administrative data system.
Up to seven diagnoses according to ICD-10 (The
international classification of Diseases, ICD-10) were
recorded for each patient at discharge. All diagnoses
were weighted according to Charlson comorbidity index,
a method validated to predict mortality by classifying or
weighting the patient’s comorbid conditions [22, 23].
Information about mortality was recorded from patient
administrative data system 30 days and 1 year after
patient’s inclusion in the study (the day of the prevalence
survey).
Statistical analysis
HAIs were analysed as a binary exposure variable (no
HAI, any HAI). We also analysed HAIs by type of infec-
tion (no HAI, UTI, LRTI, BSI, other HAIs, multiple
HAIs, SSI), which were mutually exclusive.
Descriptive statistics were used to quantify sample
characteristic whereas the Kaplan Meier survivor func-
tion were used to describe the percentage of survivors
after 30 days and 1 year after infection status. To test for
difference in survival functions across HAI categories,
we used the log-rank test. We further estimated the as-
sociations of HAIs with 30 days and 1 year mortality as
hazard ratios with 95 % confidence intervals (CIs) using
Cox regression models. The time from study inclusion
(i.e., date of prevalence survey) until death was used as
the measure of event free time. All patients were moni-
tored for up to 30 and 1 year. The hazard ratios were
estimated by crude models as well as after controlling
for year of inclusion (continuous), time period (categor-
ical calendar quarters), patient’s sex (woman, man),
patient’s age (continuous), type of admission to hospital
(acute, elective), surgical operation (no, yes), and use of
urinary tract catheter (no, intermittent/permanent). We
additionally adjusted for time from hospital admission to
study inclusion (i.e., the pre-prevalence period) and
Charlson comorbidity index. Because these two variables
formed a non-linear relationship with mortality or infec-
tion status, they were categorized and included as cat-
egorical model terms (6 categories each) to achieve
better adjustment. All covariates were chosen because
they have previously been strongly related with mortality
of HAIs. Finally, by visual inspection of the log-log plot
of survival, we verified that the proportional-hazards
assumption was essentially fulfilled for all variables in
the models. All analyses were performed using Stata/IC
version 14.0 (StataCorp, Texas, USA) for Windows. All
P values were two sided and values below 0.05 were
considered statistically significant.
Results
Patient characteristics and prevalence of HAIs
During the study period 19,468 patients were included,
1662 patients had HAIs and the remaining 17,806 did
not have HAIs. The overall prevalence of HAIs was
8.5 % and the prevalence of the four most frequently re-
corded types of infections was for LRTI 2.2 %, UTI
2.1 %, BSI 0.5 %, and SSI 1.6 %. Prevalence among oper-
ated patients was 4.5 % (Table 1). A general overview of
the analysed variables is shown in Table 2. Fifty-three
percent of the patients were females. The overall preva-
lence was higher in males than in females (9.7 % vs.
7.5 %) and increased with age. For the oldest patients
(>74 years old), we found a prevalence of 11.3 % vs.
2.6 % for the youngest patients (<14 years). A total of
6925 (35.6 %) patients had undergone surgery and the
prevalence of HAIs among operated patients was 15.0 %
compared to 5 % for the non-operated patients. Acute
admission patients had a higher prevalence of HAIs than
those with elective admission, 9.6 % and 6.8 %, respect-
ively. Seventeen percent of the patients had urinary tract
catheters (13.8 % permanent and 2.9 % intermittent) and
26.2 % of the patients received antibiotics. We found an
association between hospital stay before the date of
prevalence study and the prevalence of HAIs. Charlson
Table 1 Prevalence of HAIs among 19,468 patients at Haukeland
University hospital, 2004-2011
Type of infection n % (95 % CI)
All infections 1662 8.5 % (95 % CI: 8.1, 8.9)
Urinary tract 407 2.1 % (95 % CI 1.9, 2.3)
Lower respiratory 428 2.2 % (95 % CI: 2.0, 2.4)
Blood stream 89 0.5 % (95 CI: 0.4, 0.6)
Surgical site 311 1.6 % (95 % CI: 1.4, 1.8)
Surgical sitea 311 4.5 % (95 % CI: 4.2, 4.8)
aAmong 6925 operated patients
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Table 2 Characteristics of 19,468 patients with and without hospital-associated infections (HAIs) treated at Haukeland University
Hospital, 2004-2011
HAIs Prevalence of HAIs
All patients No Yes
Characteristics n (%) n (%) n (%) P valuea %
All 19468 (100) 17806 (100.0) 1662 (100.0) 8.5
Gender <0.001
Women 10140 (52.1) 9378 (52.7) 762 (45.8) 7.5
Men 9328 (47.9) 8428 (47.3) 900 (54.2) 9.7
Age (years) <0.001
0-14 2131 (10.9) 2076 (11.7) 55 (3.3) 2.6
15-34 2447 (12.6) 2331 (13.1) 116 (7.0) 4.7
35-54 3345 (17.2) 3084 (17.3) 261 (15.7) 7.8
55-74 6113 (31.4) 5498 (30.9) 615 (37.0) 10.1
>74 5432 (27.9) 4817 (27.1) 615 (37.0) 11.3
Time period 0.005
Jan-Mar 4924 (25.3) 4512 (25.3) 412 (24.8) 8.4
Apr-Jun 5010 (25.7) 4618 (25.9) 392 (23.6) 7.8
Jul-Sept 4786 (24.6) 4391 (24.7) 395 (23.8) 8.3
Oct-Dec 4748 (24.4) 4285 (24.1) 463 (27.9) 9.8
Admission type <0.001
Acute 12080 (62.3) 10918 (61.6) 1162 (70.2) 9.6
Elective 7304 (37.7) 6810 (38.4) 494 (29.8) 6.8
Surgery <0.001
No 12543 (64.4) 11920 (66.9) 623 (37.5) 5.0
Yes 6925 (35.6) 5886 (33.1) 1039 (62.5) 15.0
Urinary tract
catheter <0.001
No 16216 (83.3) 15162 (85.2) 1054 (63.4) 6.5
Yes, permanent 2682 (13.8) 2150 (12.1) 532 (32.0) 19.8
Yes, intermittent 570 (2.9) 494 (2.8) 76 (4.6) 13.3
Use of antibiotics <0.001
No 14372 (73.8) 14241 (80.0) 131 (7.9) 0.9
Yes 5096 (26.2) 3565 (20.0) 1531 (92.1) 30.0
Pre-prevalence period (days)b <0.001
2 5182 (26.6) 5112 (28.7) 70 (4.2) 1.4
3-5 4537 (23.3) 4339 (24.4) 198 (11.9) 4.4
6-9 4133 (21.2) 3756 (21.1) 377 (22.7) 9.1
10-15 2295 (11.8) 1938 (10.9) 357 (21.5) 15.6
16-30 2258 (11.6) 1814 (10.2) 444 (26.7) 19.7
>30 1063 (5.5) 847 (4.8) 216 (13.0) 20.3
Charlson comorbidity indexc <0.001
0 9758 (50.1) 9202 (51.7) 556 (33.5) 5.7
1 3464 (17.8) 3125 (17.6) 339 (20.4) 9.8
2 3234 (16.6) 2827 (15.9) 407 (24.5) 12.6
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comorbidity index up to 3 was associated with a higher
prevalence of HAI, whereas patients with a Charlson
index 4 or higher had a lower prevalence (Table 2).
Thirty day and 1 year mortality
Table 3 shows 30 day and 1 year mortality for all pa-
tients according to patient characteristics. Of all patients
909 (4.7 %) died within 30 days and 3188 (16.4 %) within
1 year. We found that mortality was higher among men
than women, whereas mortality increased with age for
both men and women. Patients with acute admission to
the hospital had higher mortality than patients with
elective admission. Increased mortality was also related
to a longer pre-prevalence period, with an exception for
patients having a pre-prevalence stay of more than
30 days. A high Charlson comorbidity index also gave
increased mortality, and for patients with a Charlson
index > 4 we found that 17.0 % and 61.4 % died within
30 days and 1 year, respectively.
Among patients with HAIs 10.8 % (95 % CI: 9.3, 12.3)
died within the first month after they were included in
the study compared to 4.1 % (95 % CI: 3.8, 4.4) in pa-
tients without HAIs. Within 1 year 28.4 % (95 % CI:
26.2, 30.6) with HAIs and 15.3 % (95 % CI: 14.7, 15.8)
without HAIs had died.
By Kaplan-Meier survival analyses we found that
patients without HAIs had a 1 year survival of 70 %,
compared to 85 % in those without HAIs (p < 0.001).
The lowest survival rates were found among patients
with LRTI and BSI. Patients with SSI had the same sur-
vival rates as those without HAIs (Fig. 2).
Following adjustment for confounding factors we found
that patients with HAIs had a significantly increased mor-
tality risk compared to patients without HAIs. Within
30 days and 1 year, patients with HAIs had an adjusted
hazard ratio (HR) of 1.5 (95 % CI: 1.3, 1.8) and 1.4 (95 %
CI: 1.2, 1.5) for death, respectively, relative to those with-
out HAIs. The highest mortality risk was observed in
patients with BSI, followed by patients with LRTI. No in-
creased risk of death was found in patients with UVI and
SSI during the follow up periods (Table 4).
Discussion
The main findings in this study were that patients with
HAIs had a higher risk of dying within 30 days and
1 year, compared to those without HAIs. BSI, LRTI and
having more than one HAIs simultaneously were associ-
ated with increased mortality, whereas patients with SSI
and UTI did not have an increased risk of dying. The
prevalence of HAIs was higher than previously reported
from our hospital [7]. The reason for this might be that
patients by definition are not at risk of acquiring infec-
tion during the first two days in hospital and that all
patients with less than two days length of stay were ex-
cluded from this study.
Only a few studies have estimated the global impact of
HAIs on mortality in hospital, and as in this study, they
are all reported increased mortality [14, 16, 17, 24].
Comparison of the results between studies remains diffi-
cult since different methods are used in the various
studies. However, in a study by Kanerva et al., based on
prevalence survey data from more than 7000 patients,
28 day mortality rate for patients with HAIs was slightly
lower than the 30 day mortality found in our study,
9.8 % and 10.8 % respectively [17].
As shown in other studies, we also found that both
patients with BSI and LRTI had increased risk of dying
during the follow-up period [14, 16]. Patients with SSI
had no increased mortality risk, the same result has also
been shown in other studies [16, 17]. We could not con-
firm that UTIs led to increased mortality, which con-
trasts with the findings from Fabbro-Peray et al. who
reported OR for death after 60 days to be 1.6 (95 % CI:
1.3-2.1) [16].
We identified several patient characteristics which in-
creased the risk of HAIs and death. Male gender, old
age, use of urinary tract catheter, longer pre-prevalence
period, and comorbidity were all factors affecting patient
outcome. These factors should always be taken into
account in assessing each patient’s risk of HAIs, and in
targeting infection control and prevention measures in
care and treatment.
To adjust for comorbidity we used the Charlson co-
morbidity index [22, 23]. An alternative method for
adjusting risk of death would have been McCabe score,
which assess patients subjectively in three different
groups (non-fatal, ultimately fatal and rapidly fatal ill-
ness). According to other studies there is a significant
correlation between Charlson index and McCabe class,
although McCabe classifications are assumed to have a
Table 2 Characteristics of 19,468 patients with and without hospital-associated infections (HAIs) treated at Haukeland University
Hospital, 2004-2011 (Continued)
3 1118 (5.7) 951 (5.3) 167 (10.0) 14.9
4 420 (2.2) 377 (2.1) 43 (2.6) 10.2
>4 1380 (7.1) 1236 (6.9) 144 (8.7) 10.4
aBy chi-square test
bTime from hospital admission to study inclusion
cInformation was missing for 94 patients on Charlson comorbidity index and 84 on admission type
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better goodness-of-fit for predicting death [16, 17].
McCabe classifications were, however, not part of the
data set in the prevalence surveys in our hospital, and
for this reason the Charlson index, which was already
available in the patient administrative system, was
utilised.
Our study has some limitations. Many people have
been involved in data collection, and in spite of written
information and validated definitions, different practices
and assessments may have influenced the results. Fur-
thermore, we did not investigate if patients without an
infection on the day of surveillance had a HAI later on
during the hospital stay. This might have resulted in
misclassification and an underestimation of the impact
of HAIs on mortality.
A possible sample bias may also have occurred since
457 out of 26,833 patents were excluded due to implaus-
ible data (Fig. 1). However, since the number of excluded
patients was relatively small, we do not assume that this
lead to a systematic bias.
We have no information about the length of stay
from admission to onset of HAI, and have used the
time from admission to prevalence survey (the pre-
prevalence period) as a surrogate for this. Especially
for types of infection with long duration, such as SSI,
the infection may have started several days before the
Table 3 Thirty day and 1 year mortality according to characteristics
of 19,468 patients treated at Haukeland University Hospital,
2004-2011
30-days mortality, 1 year mortality,
Characteristics n (%) n (%)
All 909 (4.7) 3188 (16.4)
Gender
Women 413 (4.1) 1449 (14.3)
Men 496 (5.3) 1739 (18.6)
Age (years)
0-14 7 (0.3) 19 (0.9)
15-34 8 (0.3) 45 (1.8)
35-54 46 (1.4) 259 (7.7)
55-74 309 (5.1) 1172 (19.2)
>74 539 (9.9) 1693 (31.2)
Time period
Jan-Mar 221 (4.5) 783 (15.9)
Apr-Jun 225 (4.5) 822 (16.4)
Jul-Sept 232 (4.9) 794 (16.6)
Oct-Dec 231 (4.9) 789 (16.6)
Admission type
Acute 801 (6.6) 2477 (20.5)
Elective 108 (1.5) 705 (9.7)
Surgery
No 739 (5.9) 2526 (20.1)
Yes 170 (2.5) 662 (9.6)
Urinary tract
catheter
No 526 (3.2) 2288 (14.1)
Yes, permanent 360 (13.4) 818 (30.5)
Yes, intermittent 23 (4.0) 82 (14.4)
Use of antibiotics
No 512 (3.6) 2035 (14.2)
Yes 397 (7.8) 1153 (22.6)
Pre-prevalence
period (days)a
2 100 (1.9) 505 (9.8)
3-5 180 (4.0) 558 (12.3)
6-9 209 (5.1) 750 (18.2)
10-15 163 (7.1) 555 (24.2)
16-30 182 (8.1) 583 (25.8)
>30 75 (7.1) 237 (22.3)
Charlson comorbidity indexb
0 93 (1.0) 331 (3.4)
1 150 (4.3) 462 (13.3)
Table 3 Thirty day and 1 year mortality according to characteristics
of 19,468 patients treated at Haukeland University Hospital,
2004-2011 (Continued)
2 249 (7.7) 925 (28.6)
3 134 (12.0) 449 (40.2)
4 49 (11.7) 168 (40.0)
>4 234 (17.0) 847 (61.4)
aTime from hospital admission to study inclusion
bInformation was missing for 94 patients on Charlson comorbidity index and
84 on admission type
Fig. 2 Survival of 19,468 patients with and without hospital-associated
infections (HAIs)
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prevalence survey. Follow-up time will therefore be
longer than 30 days and 1 year, and possibly different
for the various types of HAIs.
Even if Charlson index is described as an appropriate
tool to adjust for comorbidity, the use of ICD-codes has
some limitations. The sensitivity of ICD codes has varied
in published studies according to different practice of
coding in different hospitals and countries [25, 26]. Dur-
ing the long study period it is also possible that some
changes in practices for coding have occurred in our
hospital, although we have not identified any extensive
changes in these practices.
Conclusion
In this longitudinal study based on prevalence data from
a large emergency and referral teaching hospital in
Norway, we found that HAIs have severe consequences
for patients. BSI, LRTI or more than one simultaneous
HAI were independently and strongly associated with in-
creased mortality 30 days and 1 year after inclusion in
the study. Routinely collected prevalence surveillance
data, integrated with patient administrative system, is of
great value as a basis for studying long term conse-
quences of HAIs.
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Urinary tract 407 36 (8.9) 2.2 (1.6, 3.1) 0.9 (0.6, 1.3) 100 (24.6) 1.7 (1.4, 2.1) 0.9 (0.7, 1.1)
Lower respiratory 428 68 (15.9) 4.1 (3.2, 5.3) 1.9 (1.5, 2.5) 161 (37.6) 3.0 (2.5, 3.5) 1.7 (1.4, 2.0)
Blood stream 89 11 (12.4) 3.1 (1.7, 5.7) 2.7 (1.5, 4.9) 36 (40.5) 3.1 (2.3, 4.4) 3.0 (2.1, 4.1)
Other 301 36 (12.0) 3.1 (2.2, 4.3) 1.7 (1.2, 2.4) 91 (30.2) 2.2 (1.8, 2.8) 1.5 (1.2, 1.9)
>1 infection 126 16 (12.7) 3.3 (2.0, 5.4) 2.6 (1.5, 4.3) 35 (27.8) 2.0 (1.5, 2.8) 1.8 (1.3, 2.6)
Surgical sitec 311 13 (4.2) 2.4 (1.3, 4.2) 1.3 (0.7, 2.3) 49 (15.8) 2.1 (1.6, 2.8) 1.2 (0.9, 1.6)
aEstimated by Cox regression model
bAdjusted by year and calendar period of prevalence survey, patient’s sex and age, type of admission, surgery operation, use of urinary tract catheter, time from
hospital admission to study inclusion (pre-prevalence period), and Charlson comorbidity index
cAmong 6925 operated patients
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